Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

626
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
626
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

573
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
573
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

222
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
222
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

161
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
161
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Charge-Interaction-Mediated Adsorption of Human Growth Hormone on Polymeric Nanoparticles.

AAPS PharmSciTech·2026
Same author

Solid lipid nanoparticles in skin cancer: A comprehensive review of mechanism, formulation, and therapeutic advances.

Pathology, research and practice·2026
Same author

Advancing diagnostic biomarkers in Alzheimer's disease: interdisciplinary innovations and technological frontiers.

Human cell·2026
Same author

Travel microbiota: a novel frontier in travel medicine exploring microbial shifts across transportation modes.

Tropical diseases, travel medicine and vaccines·2026
Same author

A Decade of Mitochondria-Targeting Drugs in Cancer Treatment: Case Review on Mitochondria-Targeting Curcumin or Mitocurcumin.

Drug development research·2025
Same author

Evaluation of Mannitol's Crystallization Impact on the Secondary Structure of Spray-Dried recombinant human Growth Hormone (rhGH) Formulations.

Pharmaceutical research·2025

Related Experiment Video

Updated: Jan 10, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.6K

Designing GLP-1 delivery: structural perspectives and formulation approaches for optimized therapy.

Ravi Vamsi Peri1, Harsh Anchan2, Kamal Jonnalagadda2

  • 1Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, Saint Joseph's University, Philadelphia, PA, USA. periravivamsi@gmail.com.

Nutrition & Diabetes
|November 23, 2025
PubMed
Summary

Glucagon-like peptide-1 (GLP-1) analogs offer dual benefits for metabolic disorders, combining blood sugar control with weight loss. Modifications and advanced delivery enhance their therapeutic effectiveness and duration.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

589
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.9K

Related Experiment Videos

Last Updated: Jan 10, 2026

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.6K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

589
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

7.9K

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology and Pharmaceutical Sciences

Background:

  • Glucagon-like peptide-1 (GLP-1) is a key hormone for metabolic regulation, but its clinical use is limited by rapid degradation by dipeptidyl peptidase-IV (DPP-IV).
  • Short half-life and instability pose challenges for effective therapeutic application of native GLP-1 in managing metabolic disorders.

Purpose of the Study:

  • To review the origin, secretion, and limitations of GLP-1.
  • To explore diverse modification strategies and delivery systems designed to enhance the pharmacokinetic profile and efficacy of GLP-1 analogs.
  • To provide insights into developing improved treatments for metabolic disorders.

Main Methods:

  • Exploration of GLP-1's physiological role and degradation pathways.
  • Review of various chemical modification techniques: N and C-terminal modifications, fatty acid side chain modifications, and large molecule conjugation.
  • Analysis of optimized delivery strategies for sustained and controlled release of GLP-1 analogs.

Main Results:

  • Structural modifications significantly improve GLP-1 analog half-life, stability, receptor binding affinity, and bioactivity.
  • Fatty acid conjugation and large molecule conjugation are effective strategies for prolonging GLP-1 analog action.
  • Optimized delivery systems are crucial for achieving sustained therapeutic effects.

Conclusions:

  • Chemical modifications and advanced delivery systems have successfully overcome the limitations of native GLP-1.
  • GLP-1 analogs represent a promising therapeutic avenue for metabolic disorders, offering both glycemic control and weight management.
  • Continued research in this area holds potential for developing more effective and patient-friendly treatments for metabolic health.